title: Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.
abstract: Livedoid vasculopathy is characterized by painful purpuric lesions on the extremities which frequently ulcerate and heal with atrophic scarring. For many years, livedoid vasculopathy has been considered to be a primary vasculitic process. However, there has been evidence considering livedoid vasculopathy as an occlusive vasculopathy due to a hypercoagulable state. We present the case of livedoid vasculopathy in a 21-year-old female who had been suffering of painful lower extremity lesions of 3 years duration. The patient was found to be lupus anticoagulant positive and homozygous for methylenetetrahydrofolate reductase C677T mutation. The patient was successfully treated with low-molecular-weight heparin.
authors.forename: Jihane
authors.initials: J
authors.lastname: Abou Rahal
authors.forename: Rim S
authors.initials: RS
authors.lastname: Ishak
authors.forename: Zaher K
authors.initials: ZK
authors.lastname: Otrock
authors.forename: Abdul-Ghani
authors.initials: AG
authors.lastname: Kibbi
authors.forename: Ali T
authors.initials: AT
authors.lastname: Taher
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000008:administration & dosage*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D006801:Humans; D054068:Livedo Reticularis / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D016682:Lupus Coagulation Inhibitor; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D017354:Point Mutation
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D016682:Lupus Coagulation Inhibitor; C573423:MTHFR protein, human; D042965:Methylenetetrahydrofolate Reductase (NADPH2)